Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lunai Bioworks Inc.RENB · Entity 7981 | Chief Financial Officer | January 21, 2025 | February 25, 2025 |
| Telomir Pharmaceuticals, Inc.TELO · Entity 6962 | Chief Financial Officer | February 08, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lunai Bioworks Inc.
Report date January 21, 2025 · Filed February 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2035-01-21 | Direct | 250,000 |
Reported balance
After 2025-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-21 · Grant · Acquired 250,000 · Balance 250,000 F1: This option vests in eight equal quarterly installments beginning on January 6, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in eight equal quarterly installments beginning on January 6, 2025.
Telomir Pharmaceuticals, Inc.
Report date February 08, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,134 |
Reported balance
Holding disclosure · report date 2024-02-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 101,134 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2025 Filed Feb 25, 2025 18:29 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 250,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001731122-25-000293 · ownership.xml · derivative · entry 1 Fuentes Nathen · CIK 0002005072 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common stock · 250,000 shares Expires 2035-01-21 F1 · derivative.exercise_date: This option vests in eight equal quarterly installments beginning on January 6, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.